MedTrace Logo

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

NCT05286528 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1484

Last updated 2023-10-27

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary.

The primary endpoint of this study is the overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary. The Overall Survival (OS) of all enrolled patients, OS by sequence pattern and by the number of treatment lines will be analyzed.

Secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of CML, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated Thyrosine Kinase Inhibitor (TKI), distribution of the investigated TKI therapies by treatment lines

Conditions

  • Chronic Myeloid Leukaemia

Interventions

DRUG

Bosutinib

Bosutinib as prescribed in real world

DRUG

Imatinib

Imatinib as prescribed in real world

DRUG

Nilotinib

Nilotinib as prescribed in real world

DRUG

Dasatinib

Dasatinib as prescribed in real world

DRUG

Ponatinib

Ponatinib as prescribed in real world

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-18
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05286528 on ClinicalTrials.gov